Background
In tropical and subtropical areas, allergens from the dust mite species
Blomia tropicalis
are common causes of allergic rhinitis and asthma.
Blomia tropicalis
has two main allergens: Blo t 5 and Blo t 21.
Aim
To generate a chimeric virus-like particle containing HBcAg, Blo t 5 and Blo t 21 that can treat allergies caused by
Blomia tropicalis
.
Methods
To produce allergic asthma in mice, prokaryotic expression and purification of
Blomia tropicalis
allergens rBlo t 5, rBlo t 21, and recombinant fusion allergen rBlo t 5–21 were utilized in the study. We created a hepatitis B core antigen (HBcAg) and rBlo t 5–21 fusion prokaryotic expression plasmid. HBcAg-rBlo t 5–21 was purified after expression and tested by transmission electron microscopy (TEM). Furthermore, the protein HBcAg-rBlo t 5–21 was employed as a protein vaccination.
Results
In allergy-induced mouse model experiments, the fusion allergen rBlo t 5–21 was more effective than the individual allergens rBlo t 5 and rBlo t 21 at inducing allergy. We found that vaccinating allergic mice with the recombinant fusion protein vaccine HBcAg-rBlo t 5–21 alleviated allergy symptoms elicited by the rBlo t 5–21 allergen. Vaccination with HBcAg-rBlo t 5–21 resulted in a decrease in total serum IgE levels, suppression of anaphylaxis, and reduction of inflammatory cell infiltration into lung tissue as compared to the PBS group.
Conclusion
HBcAg-rBlo t 5–21, a protein vaccine containing both the hepatitis B core antigen and the
Blomia tropicalis
fusion allergen rBlo t 5–21, could be a suitable vaccination for preventing allergy disorders caused by
Blomia tropicalis
.